TMCnet News
Muscular Dystrophy - Pipeline Review, H2 2017 - Research and MarketsThe "Muscular Dystrophy - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 1, 27 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/8wpxjp/muscular View source version on businesswire.com: http://www.businesswire.com/news/home/20171123005198/en/ |
